Primo Brands Corporation Class A Common Stock vs Tempus AI — how do they compare? Primo Brands Corporation Class A Common Stock trades at $18.64 (market cap $6.84B), while Tempus AI trades at $66.83 (market cap $12.39B). The key difference: Tempus AI is the larger of the two by market cap, and Primo Brands Corporation Class A Common Stock pays a 2.54% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Primo Brands Corporation Class A Common Stock for 0 Days and Tempus AI for 23 Days on average.
| PRMB | TEM | |
|---|---|---|
Market Cap | $6.84B | $12.39B |
Volume | 2,864,594 | 4,141,569 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $25.39 | $92.45 |
52-Week Low | $14.46 | $41.55 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $12.17B | $13.01B |
Dividend Yield | 2.54% | — |
Signals from Pluang's Aura AI — not financial advice
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
Tempus AI (TEM) trades at $68.22, up 0.34% with a bullish technical signal despite negative profitability. The stock shows strong analyst support with 64% buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and ESMO conference presentations highlight ongoing innovation, while Q2 2026 earnings beat expectations with 22% revenue growth. Cash flow remains positive primarily from financing activities.
While TEM demonstrates strong revenue growth and product innovation, significant risks persist including negative net margins (-17.77%) and substantial insider selling. The stock's high P/B ratio of 27.84 suggests premium valuation despite unprofitability. Near-term catalysts include Q3 earnings and ESMO presentations, but investors should weigh growth potential against persistent losses and competitive pressures in AI healthcare.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →